Platelets Mediate Oxidized Low-density Lipoprotein-induced Monocyte Extravasation and Foam Cell Formation
Overview
Authors
Affiliations
Objective: A growing body of evidence indicates that platelets contribute to the onset and progression of atherosclerosis by modulating immune responses. We aimed to elucidate the effects of oxidized low-density lipoprotein (OxLDL) on platelet-monocyte interactions and the consequences of these interactions on platelet phagocytosis, chemokine release, monocyte extravasation, and foam cell formation.
Approach And Results: Confocal microscopy and flow cytometric analysis revealed that in vitro and in vivo stimulation with OxLDL resulted in rapid formation of platelet-monocyte aggregates, with a preference for CD16+ monocyte subsets. This platelet-monocyte interaction facilitated OxLDL uptake by monocytes, in a process that involved platelet CD36-OxLDL interaction, release of chemokines, such as CXC motif ligand 4, direct platelet-monocyte interaction, and phagocytosis of platelets. Inhibition of cyclooxygenase with acetylsalicylic acid and antagonists of ADP receptors, P2Y1 and P2Y12, partly abrogated OxLDL-induced platelet-monocyte aggregates and platelet-mediated lipid uptake in monocytes. Platelets also enhanced OxLDL-induced monocyte transmigration across an endothelial monolayer via direct interaction with monocytes in a transwell assay. Importantly, in LDLR(-/-) mice, platelet depletion resulted in a significant decrease of peritoneal macrophage recruitment and foam cell formation in a thioglycollate-elicited peritonitis model. In platelet-depleted wild-type mice, transfusion of ex vivo OxLDL-stimulated platelets induced monocyte extravasation to a higher extent when compared with resting platelets.
Conclusions: Our results on OxLDL-mediated platelet-monocyte aggregate formation, which promoted phenotypic changes in monocytes, monocyte extravasation and enhanced foam cell formation in vitro and in vivo, provide a novel mechanism for how platelets potentiate key steps of atherosclerotic plaque development and plaque destabilization.
Evaluation of pseudoexfoliation syndrome patients with systemic immune indexes.
Ozer O, Guclu E BMC Ophthalmol. 2024; 24(1):494.
PMID: 39533247 PMC: 11555842. DOI: 10.1186/s12886-024-03767-1.
Cao Z, Jiang X, He Y, Zheng X Ann Med. 2024; 56(1):2401112.
PMID: 39297312 PMC: 11413966. DOI: 10.1080/07853890.2024.2401112.
Scalia A, Coquay M, Kindt N, Duez P, Aro R, Journe F Int J Mol Sci. 2024; 25(17).
PMID: 39273434 PMC: 11394959. DOI: 10.3390/ijms25179487.
Lesouhaitier M, Belicard F, Tadie J Crit Care. 2024; 28(1):300.
PMID: 39256830 PMC: 11389086. DOI: 10.1186/s13054-024-05058-z.
Bulnes J, Gonzalez L, Velasquez L, Orellana M, Munoz Venturelli P, Martinez G Front Cardiovasc Med. 2024; 11:1356023.
PMID: 38993522 PMC: 11236697. DOI: 10.3389/fcvm.2024.1356023.